MX2020008076A - Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. - Google Patents
Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.Info
- Publication number
- MX2020008076A MX2020008076A MX2020008076A MX2020008076A MX2020008076A MX 2020008076 A MX2020008076 A MX 2020008076A MX 2020008076 A MX2020008076 A MX 2020008076A MX 2020008076 A MX2020008076 A MX 2020008076A MX 2020008076 A MX2020008076 A MX 2020008076A
- Authority
- MX
- Mexico
- Prior art keywords
- salts
- making
- methods
- same
- formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se divulgan sales, hidratos y solvatos del Compuesto I y métodos para hacer y usar el mismo y las formas de dosificación relacionadas del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018075023 | 2018-02-02 | ||
| PCT/US2019/016386 WO2019152863A1 (en) | 2018-02-02 | 2019-02-01 | Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008076A true MX2020008076A (es) | 2020-09-24 |
Family
ID=65494537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008076A MX2020008076A (es) | 2018-02-02 | 2019-02-01 | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. |
| MX2020011756A MX2020011756A (es) | 2018-02-02 | 2020-07-30 | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011756A MX2020011756A (es) | 2018-02-02 | 2020-07-30 | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20200361933A1 (es) |
| EP (1) | EP3746441B1 (es) |
| JP (2) | JP7372926B2 (es) |
| KR (2) | KR20260007293A (es) |
| CN (2) | CN117247383A (es) |
| AR (1) | AR114090A1 (es) |
| AU (3) | AU2019215172B2 (es) |
| BR (1) | BR112020015759A2 (es) |
| CA (1) | CA3090270A1 (es) |
| ES (1) | ES2949662T3 (es) |
| HR (1) | HRP20230645T1 (es) |
| IL (2) | IL312673A (es) |
| MX (2) | MX2020008076A (es) |
| PL (1) | PL3746441T3 (es) |
| SG (1) | SG11202007726RA (es) |
| SI (1) | SI3746441T1 (es) |
| TW (2) | TW202426448A (es) |
| WO (1) | WO2019152863A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761001A (zh) | 2019-12-04 | 2022-07-15 | 爱杜西亚药品有限公司 | 氮杂环丁烷lpa1受体拮抗剂与抗纤维化药剂的组合 |
| CN114129517A (zh) * | 2020-09-03 | 2022-03-04 | 苏州爱科百发生物医药技术有限公司 | 一种ak3287制剂及其制备方法和应用 |
| CN116509850A (zh) * | 2022-01-21 | 2023-08-01 | 苏州爱科百发生物医药技术有限公司 | N-芳基吡啶酮类化合物在尘肺治疗中的用途 |
| JPWO2023219106A1 (es) * | 2022-05-10 | 2023-11-16 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5267900A (en) | 1999-05-07 | 2000-11-21 | Texas Biotechnology Corporation | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| JP5421783B2 (ja) * | 2006-12-27 | 2014-02-19 | サノフイ | Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体 |
| EP2389227A4 (en) | 2009-01-26 | 2012-08-08 | Intermune Inc | METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF |
| CN102325765B (zh) * | 2009-02-06 | 2014-12-24 | 杨森制药公司 | 作为γ-分泌酶调节剂的取代的双环杂环化合物 |
| WO2011055270A1 (en) * | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
| CN102952138B (zh) * | 2011-08-17 | 2016-07-06 | 上海特化医药科技有限公司 | 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用 |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US20140094456A1 (en) * | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| US10233195B2 (en) * | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
| RS62466B1 (sr) * | 2015-12-02 | 2021-11-30 | Merck Sharp & Dohme | Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin |
-
2019
- 2019-02-01 ES ES19706097T patent/ES2949662T3/es active Active
- 2019-02-01 EP EP19706097.3A patent/EP3746441B1/en active Active
- 2019-02-01 KR KR1020257042192A patent/KR20260007293A/ko active Pending
- 2019-02-01 IL IL312673A patent/IL312673A/en unknown
- 2019-02-01 HR HRP20230645TT patent/HRP20230645T1/hr unknown
- 2019-02-01 TW TW113105119A patent/TW202426448A/zh unknown
- 2019-02-01 PL PL19706097.3T patent/PL3746441T3/pl unknown
- 2019-02-01 MX MX2020008076A patent/MX2020008076A/es unknown
- 2019-02-01 SI SI201930569T patent/SI3746441T1/sl unknown
- 2019-02-01 SG SG11202007726RA patent/SG11202007726RA/en unknown
- 2019-02-01 CA CA3090270A patent/CA3090270A1/en active Pending
- 2019-02-01 TW TW108104308A patent/TWI834634B/zh active
- 2019-02-01 BR BR112020015759-7A patent/BR112020015759A2/pt unknown
- 2019-02-01 CN CN202311023046.0A patent/CN117247383A/zh active Pending
- 2019-02-01 CN CN201980014188.6A patent/CN112105616B/zh active Active
- 2019-02-01 AR ARP190100236A patent/AR114090A1/es unknown
- 2019-02-01 US US16/966,384 patent/US20200361933A1/en not_active Abandoned
- 2019-02-01 JP JP2020541912A patent/JP7372926B2/ja active Active
- 2019-02-01 KR KR1020207025151A patent/KR102903080B1/ko active Active
- 2019-02-01 WO PCT/US2019/016386 patent/WO2019152863A1/en not_active Ceased
- 2019-02-01 AU AU2019215172A patent/AU2019215172B2/en active Active
- 2019-02-01 IL IL276430A patent/IL276430B2/en unknown
-
2020
- 2020-07-30 MX MX2020011756A patent/MX2020011756A/es unknown
-
2023
- 2023-08-02 JP JP2023126415A patent/JP2023145680A/ja active Pending
- 2023-08-31 AU AU2023222929A patent/AU2023222929B2/en active Active
-
2024
- 2024-06-18 US US18/747,301 patent/US20240409539A1/en active Pending
-
2025
- 2025-12-18 AU AU2025283559A patent/AU2025283559A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| MX2020011745A (es) | Terapias genicas para los trastornos lisosomales. | |
| CY1123801T1 (el) | Παραγωγα αρωματικου σουλφοναμιδιου | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| UY38353A (es) | Inhibición de integrina alfavbeta6 | |
| MX2019012434A (es) | Agentes inductores de apoptosis. | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| UY36654A (es) | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| JOP20190174A1 (ar) | مثبطات jak1 انتقائية | |
| CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| MX2018013387A (es) | Inhibidores de la arginasa y sus aplicaciones terapeuticas. | |
| CL2020002624A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| BR112018071370A2 (pt) | composições farmacêuticas orais de mesalazina | |
| UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
| CO2019008110A2 (es) | Activador de nrf2 | |
| MX2018013573A (es) | Ciertos inhibidores de la proteína cinasa. |